ENTX: Entera Bio Ltd. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 68.14
Enterprise Value ($M) 61.22
Book Value ($M) 6.45
Book Value / Share 0.18
Price / Book 10.56
NCAV ($M) 6.05
NCAV / Share 0.16
Price / NCAV 11.26

Profitability (mra)
Return on Invested Capital (ROIC) -1.36
Return on Assets (ROA) -0.78
Return on Equity (ROE) -0.88

Liquidity (mrq)
Quick Ratio 6.61
Current Ratio 6.61

Balance Sheet (mrq) ($M)
Current Assets 7.34
Assets 7.74
Liabilities 1.29
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
01-06 13G Point72 Asset Management, L.P. 6.80
11-20 13G/A Knoll Capital Management, LLC 15.00 51.52
08-20 13G/A Centillion Fund Inc. 6.70 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-10 10-Q UNITED STATES

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-14 2,479 25,321 9.79
2025-03-13 7,509 53,457 14.05
2025-03-12 1,882 35,900 5.24
2025-03-11 20,781 99,421 20.90
2025-03-10 6,383 78,746 8.11

(click for more detail)

Similar Companies
ENLV – Enlivex Therapeutics Ltd. ENSC – Ensysce Biosciences, Inc.
ENTO – Entero Therapeutics, Inc. ENVB – Enveric Biosciences, Inc.
EPIX – ESSA Pharma Inc.


Financial data and stock pages provided by
Fintel.io